medigraphic.com
Colegio de Medicina Interna de México.

2024, Number 1

<< Back Next >>

Med Int Mex 2024; 40 (1)

Drug neuro-rehabilitation in the cerebral infarction: The potential of cerebrolysin

Cantú BC

Language: Spanish
References: 36
Page: 36-49
PDF size: 288.76 Kb.


ABSTRACT

Worldwide, cerebral vascular disease is the second cause of death and the main cause of disability. It is estimated that, from the age of 25, 1 in every 4 people in the world will suffer a cerebrovascular event in their lifetime. Cerebrolysin has neuroprotective and neurorepair properties. This paper communicates the findings of different studies of the role of cardiolysin in neuroprotection.


REFERENCES

  1. Roth GA, Mensah GA, Johnson CO, Addolorato G, AmmiratiE, Baddour LM, et al, the GBD-NHLBI-JACC Global Burdenof Cardiovascular Diseases Writing Group. Global Burden ofCardiovascular Diseases and Risk Factors, 1990-2019. UpdateFrom the GBD 2019 Study. JACC 2020; 76: 2982–3021.

  2. GBD 2019 Stroke Collaborators. Global, regional, and nationalburden of stroke and its risk factors, 1990-2019: asystematic analysis for the Global Burden of Disease Study2019. Lancet Neurol 2021; 20: 795-820. doi: 10.1016/S1474-4422(21)00252-0.

  3. Ouriques Martins SC, Sacks C, Hacke W, Brainin M, de AssisFigueiredo F, Marques Pontes-Neto O, et al. Priorities toreduce the burden of stroke in Latin American countries.Lancet Neurol 2019; 18 (7): 674-683. doi: 10.1016/S1474-4422(19)30068-7.

  4. De la Cruz-Góngora V, Chiquete E, Gómez−Dantés H,Cahuana-Hurtado L, Cantú-Brito C. Trends in the burdenof stroke in Mexico: A national and subnational analysis ofthe global burden of disease 1990−2019. Lancet Reg HealthAm 2022; 10: 100204. doi: 10.1016/j.lana.2022.100204.

  5. Gorelick PB. The global burden of stroke: persistent anddisabling. Lancet Neurol 2019; 18: 417-418. doi: 10.1016/S1474-4422(19)30030-4.

  6. Winstein CJ, Stein J, Arena R, Bates B, Cherney LR, CramerSC, et al. Guidelines for adult stroke rehabilitationand recovery: a guideline for healthcare professionalsfrom the American Heart Association/American StrokeAssociation. Stroke 2016; 47: e98-e169. doi: 10.1161/STR.0000000000000098.

  7. van der Vliet R, Selles RW, Andrinopoulou ER, Nijland R,Ribbers GM, Frens MA, et al. Predicting upper limb motorimpairment recovery after stroke: a mixture model. AnnNeurol 2020; 87: 383-393. doi: 10.1002/ana.25679.

  8. Gladstone DJ, Danells CJ, Black SE. The fugl-meyer assessmentof motor recovery after stroke: a critical review ofits measurement properties. Neurorehabil Neural Repair2002; 16: 232-240. doi: 10.1177/154596802401105171.

  9. Blizniewska-Kowalska K, Lukasik M, Galecki P. Cerebrolysin– mechanism of action and application in psychiatry andneurology. Farmakoterapia w Psychiatrii i Neurologii 2019;35: 9-23. DOI: https://doi.org/10.33450/fpn.2019.03.002.

  10. Fiani B, Covarrubias C, Wong A, Doan T, Reardon T, NikolaidisD, Sarno E. Cerebrolysin for stroke, neurodegeneration,and traumatic brain injury: review of the literature andoutcomes. Neurol Sci 2021; 42: 1345-1353. doi: 10.1007/s10072-021-05089-2.

  11. Zhang L, Chopp M, Meier DH, Winter S, Wang L, SzaladA, et al. Sonic hedgehog signaling pathway mediatescerebrolysin-improved neurological function after stroke.Stroke 2013; 44: 1965-1972. https://doi.org/10.1161/STROKEAHA.111.000831.

  12. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, BambakidisNC, Becker K, et al. Guidelines for the early managementof patients with acute ischemic stroke: 2019 Updateto the 2018 Guidelines for the Early Management of AcuteIschemic Stroke: A Guideline for Healthcare Professionalsfrom the American Heart Association/American StrokeAssociation. Stroke 2019; 50 (12): e344-e418. https://doi.org/10.1161/STR.0000000000000211.

  13. Chamorro Á, Dirnagl U, Urra X, Planas AM. Neuroprotectionin acute stroke: targeting excitotoxicity, oxidativeand nitrosative stress, and inflammation. Lancet Neurol2016; 15: 869-881. https://doi.org/10.1016/S1474-4422(16)00114-9.

  14. Hill MD, Goyal M, Menon BK, Nogueira RG, McTaggart RA,Demchuk AM, et al. Efficacy and safety of nerinetide for thetreatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre,double-blind, randomised controlled trial. Lancet2020; 395: 878-887. doi: 10.1016/S0140-6736(20)30258-0.

  15. Ladurner G, Kalvach P, Moessler H. Cerebrolysin studygroup. Neuroprotective treatment with cerebrolysin inpatients with acute stroke: a randomised controlled trial. JNeural Transm (Vienna) 2005; 112: 415-428. doi: 10.1007/s00702-004-0248-2.

  16. Lang W, Ch S, Poljakovic Z, et al. Lyse study group. A prospective,randomized, placebo-controlled, double-blindtrial about safety and efficacy of combined treatmentwith alteplase (rt-pa) and cerebrolysin in acute ischaemichemispheric stroke. Int J Stroke 2013; 8: 95-104. doi:10.1111/j.1747-4949.2012.00901.x.

  17. Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z,for the Cerebrolysin Acute Stroke Treatment in Asia (CASTA)Investigators. Cerebrolysin in patients with acute ischemicstroke in Asia. Stroke 2021; 43: 630-636. doi: 10.1161/STROKEAHA.111.628537.

  18. Gharagozli K, Harandi AA, Houshmand S, Akbari N, MuresanuDF, Vester J, Winter S, Moessler H. Efficacy, andsafety of Cerebrolysin treatment in early recovery afteracute ischemic stroke: a randomized, placebo-controlled,double-blinded, multi- center clinical trial. J Med Life 2017;10: 153-160.

  19. Ziganshina LE, Abakumova T, Hoyle CH. Cerebrolysin foracute ischaemic stroke. Cochrane Database Syst Rev 2020;7: CD007026.

  20. Muresanu DF, Strilciuc S, Stan A. Current drug treatmentof acute ischemic stroke: challenges and opportunities.CNS Drugs 2019; 33: 841-847. doi: 10.1007/s40263-019-00663-x.

  21. Zhang C, Chopp M, Cui Y, Wang L, Zhang R, Zhang L, et al.Cerebrolysin enhances neurogenesis in the ischemic brainand improves functional outcome after stroke. J NeurosciRes 2010; 88: 3275-3281. doi: 10.1002/jnr.22495.

  22. Brainin M. Cerebrolysin: a multi-target drug for recoveryafter stroke. Expert Rev Neurother 2018; 18: 681-687. doi:10.1080/14737175.2018.1500459.

  23. Muresanu DF, Heiss WD, Hoemberg V, Bajenaru O, PopescuCD, Vester JC, et al. Cerebrolysin and Recovery After Stroke(CARS): A randomized, placebo-controlled, double-blind,multicenter trial. Stroke 2016; 47: 151-159. doi: 10.1161/STROKEAHA.115.009416.

  24. Lyle RC. A performance test for assessment of upper limbfunction in physical rehabilitation treatment and research.Int J Rehabil Res 1981; 4: 483-492. doi: 10.1097/00004356-198112000-00001.

  25. Goodglass H and Kaplan E. The assessment of aphasiaand related disorders. 2nd ed. Philadelphia, PA: Lea &Febiger; 1983.

  26. Guekht A, Heiss D, Gusev E, Vester J, Doppler E, MuresanuD. Cerebrolysin and recovery after stroke (CARS 2): a randomized,placebo-controlled, double-blind multicenterclinical study. J Neurol Sci 2015; 357: e103. DOI:https://doi.org/10.1016/j.jns.2015.08.336.

  27. Guekht A, Vester J, Heiss WD, Gusev E, Hoemberg V, RahlfsVW, et al. Safety and efficacy of Cerebrolysin in motorfunction recovery after stroke: a meta-analysis of theCARS trials. Neurol Sci 2017; 38: 1761-1769. doi: 10.1007/s10072-017-3037-z.

  28. DeBoer SR, Hubbard R, Mersha M, Pinilla MonsalveG, Winter S, Zeiler SR. Enhanced spontaneous motorrecovery after stroke in mice treated with cerebrolysin.Neurorehabil Neural Repair 2021; 35: 525-533. doi:10.1177/15459683211000734.

  29. Chang WH, Park CH, Kim DY, Shin YI, Ko MH, Lee A, et al. Cerebrolysincombined with rehabilitation promotes motor recoveryin patients with severe motor impairment after stroke.BMC Neurol 2016; 16: 31. doi: 10.1186/s12883-016-0553-z.

  30. Chang WH, Lee J, Shin YI, Ko MH, Kim DY, Sohn MK, et al.Cerebrolysin combined with rehabilitation enhances motorrecovery and prevents neural network degeneration inischemic stroke patients with severe motor deficits. J PersMed 2021; 11: 545. doi: 10.3390/jpm11060545.

  31. Stinear CM, Lang CE, Zeiler S, Byblow WD. Advances, andchallenges in stroke rehabilitation. Lancet Neurol 2020; 19:348-360. doi: 10.1016/S1474-4422(19)30415-6.

  32. Gittler M, Davis AM. Guidelines for adult stroke rehabilitationand recovery. JAMA 2018; 319: 820-821. doi:10.1001/jama.2017.22036.

  33. Beghi E, Binder H, Birle C, Bornstein N, Diserens K, GroppaS, et al. European Academy of Neurology and EuropeanFederation of Neurorehabilitation Societies guideline onpharmacological support in early motor rehabilitation afteracute ischaemic stroke. Eur J Neurol 2021; 28: 2831-2845.doi: 10.1111/ene.14936.

  34. Austrian Guideline of Neurorehabilitation after stroke;2018. https://www.xn-gsf-rna.at/wpcontent/uploads/2016/11/Positionspapier2018_OEGSF_neurologisch.

  35. Platz T. S3 guideline “Rehabilitative therapy for arm paresisfollowing a stroke” of the German Society for Neurorehabilitation.https://cerebrolysin.com.ua/fileadmin/user_upload/materials/protocols/DGNR-S3-Guideline_English-Translation.pdf.

  36. Canadian Stroke Rehabilitation Evidence Based Review(16th edition) section 4.3.23 (Peptides); 2020.




2020     |     www.medigraphic.com